BioVentrix has received an extension of its CE mark for the Revivent TC transcatheter ventricular enhancement system to May 2024. The company received its initial CE mark in 2016.
Less invasive ventricular enhancement (LIVE) therapy uses the Revivent TC system to exclude scar tissue on the left ventricle that has occurred from a myocardial infarction so the healthy portion of the heart can operate more efficiently. Micro-anchors are implanted and designed to remodel the heart to a more normal shape and size and reduce wall stress, which has been shown to improve blood flow throughout the body.
Kenneth Miller, president and CEO of BioVentrix, comments: “The extension of our CE mark is not only an important milestone for the company, but also validates the need for a novel therapy for patients with left ventricular dysfunction who are among the estimated 10 million people in the European Union with heart failure. It ensures that physicians will continue to have an important, less invasive therapeutic option for these patients.”